We found a match
Your institution may have access to this item. Find your institution then sign in to continue.
- Title
Discontinuation of tyrosine kinase inhibitors in chronic myeloid leukemia: Recommendations for clinical practice from the French Chronic Myeloid Leukemia Study Group.
- Authors
Rea, Delphine; Ame, Shanti; Berger, Marc; Cayuela, Jean‐Michel; Charbonnier, Aude; Coiteux, Valérie; Cony‐Makhoul, Pascale; Dubruille, Viviane; Dulucq, Stéphanie; Etienne, Gabriel; Legros, Laurence; Nicolini, Franck; Roche‐Lestienne, Catherine; Escoffre‐Barbe, Martine; Gardembas, Martine; Guerci‐Bresler, Agnès; Johnson‐Ansah, Hyacinthe; Rigal‐Huguet, Françoise; Rousselot, Philippe; Mahon, François‐Xavier
- Abstract
<bold>Background: </bold>The ultimate goal of chronic myeloid leukemia management in the tyrosine kinase inhibitor (TKI) era for patients who obtain deep molecular responses is maintaining a durable off-treatment response after treatment discontinuation; this situation is called treatment-free remission (TFR). Knowledge accumulated during the last 10 years justifies moving TFR strategies from research to clinical practice.<bold>Methods: </bold>Twenty experts from the French Chronic Myeloid Leukemia Study Group (France Intergroupe des Leucémies Myéloïdes Chroniques), including 17 hematologists, 2 molecular biologists, and 1 cytogeneticist, critically reviewed published data with the goal of developing evidence-based recommendations for TKI discontinuation in clinical practice.<bold>Results: </bold>Clinically relevant questions were addressed, including the selection of candidate patients (with known prognostic factors for outcomes taken into account), detailed monitoring procedures during the treatment-free phase, a definition of relapse requiring therapy resumption, and monitoring after treatment reintroduction.<bold>Conclusions: </bold>This work presents consensus statements with the aim of guiding physicians and biologists by means of pragmatic recommendations for safe TKI discontinuation in daily practice. Cancer 2018;124:2956-63. © 2018 American Cancer Society.
- Subjects
PROTEIN-tyrosine kinase inhibitors; TREATMENT of chronic myeloid leukemia; HEMATOLOGISTS; CYTOGENETICISTS; CANCER relapse
- Publication
Cancer (0008543X), 2018, Vol 124, Issue 14, p2956
- ISSN
0008-543X
- Publication type
journal article
- DOI
10.1002/cncr.31411